Theratechnologies Inc. is a biopharmaceutical company that specializes in therapeutic peptide products, with an emphasis on growth-hormone releasing factor (GRF) peptides. The Company’s product, EGRIFTA (tesamorelin for injection), is approved by the United States Food and Drug Administration indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. EGRIFTA is commercialized in the United States by EMD Serono, Inc.
